Oncobiologics (NASDAQ:OTLK) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Oncobiologics (NASDAQ:OTLK) announced its quarterly earnings data on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01), FiscalAI reports. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.97 million.

Oncobiologics Stock Down 14.9%

Shares of NASDAQ OTLK traded down $0.13 during mid-day trading on Friday, reaching $0.76. 104,469,209 shares of the company were exchanged, compared to its average volume of 17,814,098. The stock has a market capitalization of $112.39 million, a PE ratio of -0.65 and a beta of 0.82. The company’s 50 day moving average price is $1.31 and its 200 day moving average price is $0.70. Oncobiologics has a 52 week low of $0.16 and a 52 week high of $3.39.

More Oncobiologics News

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and set a $4.00 price target, implying significant potential upside from recent trading levels. Benzinga analyst rating report
• Positive Sentiment: Management highlighted FDA approval of LYTENAVA, an ophthalmic bevacizumab product intended to address the U.S. wet age-related macular degeneration market. The approval could support future commercialization and revenue growth. Outlook Therapeutics third-quarter results and business update
• Positive Sentiment: Director Ghiath M. Sukhtian purchased 2.53 million shares for approximately $2.5 million, increasing his direct ownership by 11.43%. The insider purchase may be viewed as a vote of confidence in the company’s prospects. SEC insider transaction filing
• Neutral Sentiment: The company’s quarterly loss was $0.09 per share, compared with a $0.44 loss a year earlier, indicating year-over-year improvement but still missing the $0.08 consensus estimate. Zacks quarterly earnings report
• Negative Sentiment: Revenue was only approximately $10,000, far below the $970,000 consensus estimate. The revenue shortfall reinforces concerns about the timing of LYTENAVA’s commercial ramp and near-term cash generation. MarketBeat earnings report
• Negative Sentiment: Oncobiologics priced a $55 million public offering of 55.56 million shares at $0.99 each, along with immediately exercisable warrants carrying a $1.10 strike price. The large offering creates substantial dilution and likely contributed to selling pressure. Public offering announcement

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on OTLK shares. Wall Street Zen lowered shares of Oncobiologics from a “hold” rating to a “sell” rating in a research note on Saturday. BTIG Research reaffirmed a “buy” rating and issued a $4.00 price target on shares of Oncobiologics in a report on Friday. Weiss Ratings upgraded Oncobiologics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. HC Wainwright boosted their price objective on Oncobiologics to $1.60 and gave the company a “neutral” rating in a research note on Monday, July 27th. Finally, Ascendiant Capital Markets raised their target price on Oncobiologics from $6.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, June 11th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $4.65.

Insider Activity at Oncobiologics

In related news, Director Ghiath M. Sukhtian bought 8,539,709 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was purchased at an average cost of $0.59 per share, with a total value of $5,038,428.31. Following the transaction, the director owned 22,092,068 shares in the company, valued at approximately $13,034,320.12. This trade represents a 63.01% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Faisal Ghiath Sukhtian acquired 95,398 shares of the stock in a transaction on Wednesday, July 29th. The shares were purchased at an average cost of $1.05 per share, with a total value of $100,167.90. Following the transaction, the director directly owned 220,972 shares of the company’s stock, valued at approximately $232,020.60. This trade represents a 75.97% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have purchased 11,189,359 shares of company stock worth $7,662,666. 1.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its stake in shares of Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after acquiring an additional 44,063 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Oncobiologics by 42.7% in the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock worth $103,000 after purchasing an additional 25,351 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in Oncobiologics by 865.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after purchasing an additional 21,941 shares in the last quarter. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.